Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.84
LGND's Cash to Debt is ranked higher than
56% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. LGND: 0.84 )
LGND' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 0.84

Equity to Asset 0.10
LGND's Equity to Asset is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. LGND: 0.10 )
LGND' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.47
Current: 0.1

-0.49
0.47
F-Score: 7
Z-Score: 1.27
M-Score: -0.07
WACC vs ROIC
11.64%
37.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 30.41
LGND's Operating margin (%) is ranked higher than
96% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. LGND: 30.41 )
LGND' s 10-Year Operating margin (%) Range
Min: -1963.29   Max: 30.51
Current: 30.41

-1963.29
30.51
Net-margin (%) 18.63
LGND's Net-margin (%) is ranked higher than
93% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. LGND: 18.63 )
LGND' s 10-Year Net-margin (%) Range
Min: -798.16   Max: 2184.64
Current: 18.63

-798.16
2184.64
ROE (%) 24.10
LGND's ROE (%) is ranked higher than
96% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. LGND: 24.10 )
LGND' s 10-Year ROE (%) Range
Min: -1046.55   Max: 997.71
Current: 24.1

-1046.55
997.71
ROA (%) 7.15
LGND's ROA (%) is ranked higher than
93% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. LGND: 7.15 )
LGND' s 10-Year ROA (%) Range
Min: -95.66   Max: 112.83
Current: 7.15

-95.66
112.83
ROC (Joel Greenblatt) (%) 3054.31
LGND's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. LGND: 3054.31 )
LGND' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1430.01   Max: 2901.11
Current: 3054.31

-1430.01
2901.11
Revenue Growth (3Y)(%) 25.60
LGND's Revenue Growth (3Y)(%) is ranked higher than
91% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. LGND: 25.60 )
LGND' s 10-Year Revenue Growth (3Y)(%) Range
Min: -64.8   Max: 90.1
Current: 25.6

-64.8
90.1
EBITDA Growth (3Y)(%) 126.10
LGND's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. LGND: 126.10 )
LGND' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.8   Max: 126.1
Current: 126.1

-56.8
126.1
EPS Growth (3Y)(%) 4.60
LGND's EPS Growth (3Y)(%) is ranked higher than
82% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. LGND: 4.60 )
LGND' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.9   Max: 27.7
Current: 4.6

-52.9
27.7
» LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LGND Guru Trades in Q1 2014

Steven Cohen 4,601 sh (New)
Paul Tudor Jones 4,252 sh (New)
RS Investment Management 1,315,098 sh (unchged)
Joel Greenblatt Sold Out
RS Investment Management 1,222,507 sh (-7.04%)
» More
Q2 2014

LGND Guru Trades in Q2 2014

Jim Simons 38,594 sh (New)
Joel Greenblatt 55,492 sh (New)
Ken Fisher 36,908 sh (New)
RS Investment Management 1,392,185 sh (+13.88%)
Paul Tudor Jones Sold Out
» More
Q3 2014

LGND Guru Trades in Q3 2014

Paul Tudor Jones 5,200 sh (New)
Joel Greenblatt 552,053 sh (+894.83%)
RS Investment Management 1,493,635 sh (+7.29%)
Jim Simons Sold Out
Ken Fisher 35,258 sh (-4.47%)
» More
Q4 2014

LGND Guru Trades in Q4 2014

Ken Fisher 81,908 sh (+132.31%)
RS Investment Management 1,430,650 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management 1,430,650 sh (-4.22%)
Joel Greenblatt 3,766 sh (-99.32%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 128.20
LGND's P/E(ttm) is ranked higher than
88% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 128.20 )
LGND' s 10-Year P/E(ttm) Range
Min: 0.99   Max: 269.4
Current: 128.2

0.99
269.4
Forward P/E 25.45
LGND's Forward P/E is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 25.45 )
N/A
PE(NRI) 128.00
LGND's PE(NRI) is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 128.00 )
LGND' s 10-Year PE(NRI) Range
Min: 23.18   Max: 99999999.99
Current: 128

23.18
99999999.99
P/B 54.44
LGND's P/B is ranked lower than
55% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. LGND: 54.44 )
LGND' s 10-Year P/B Range
Min: 11.11   Max: 182
Current: 54.44

11.11
182
P/S 24.00
LGND's P/S is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. LGND: 24.00 )
LGND' s 10-Year P/S Range
Min: 3.13   Max: 754
Current: 24

3.13
754
PFCF 130.27
LGND's PFCF is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 130.27 )
LGND' s 10-Year PFCF Range
Min: 33.11   Max: 425.29
Current: 130.27

33.11
425.29
POCF 75.99
LGND's POCF is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 75.99 )
LGND' s 10-Year POCF Range
Min: 20.29   Max: 249.25
Current: 75.99

20.29
249.25
EV-to-EBIT 74.19
LGND's EV-to-EBIT is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 74.19 )
LGND' s 10-Year EV-to-EBIT Range
Min: -6946.9   Max: 2376.7
Current: 74.19

-6946.9
2376.7
Shiller P/E 465.91
LGND's Shiller P/E is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 465.91 )
LGND' s 10-Year Shiller P/E Range
Min: 3.22   Max: 479.38
Current: 465.91

3.22
479.38
Current Ratio 8.13
LGND's Current Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. LGND: 8.13 )
LGND' s 10-Year Current Ratio Range
Min: 0.57   Max: 8.13
Current: 8.13

0.57
8.13
Quick Ratio 8.12
LGND's Quick Ratio is ranked higher than
85% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. LGND: 8.12 )
LGND' s 10-Year Quick Ratio Range
Min: 0.53   Max: 8.12
Current: 8.12

0.53
8.12
Days Inventory 43.93
LGND's Days Inventory is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. LGND: 43.93 )
LGND' s 10-Year Days Inventory Range
Min: 33.18   Max: 251.44
Current: 43.93

33.18
251.44
Days Sales Outstanding 71.45
LGND's Days Sales Outstanding is ranked higher than
80% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. LGND: 71.45 )
LGND' s 10-Year Days Sales Outstanding Range
Min: 5.79   Max: 1057.37
Current: 71.45

5.79
1057.37

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.03
LGND's Price/Median PS Value is ranked higher than
74% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. LGND: 2.03 )
LGND' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 17.9
Current: 2.03

0.43
17.9
Earnings Yield (Greenblatt) 1.30
LGND's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. LGND: 1.30 )
LGND' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.9
Current: 1.3

0.1
1.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.
» More Articles for LGND

Headlines

Articles On GuruFocus.com
dick Feb 13 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 

More From Other Websites
Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog Mar 10 2015
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape Mar 03 2015
Coverage initiated on Ligand Pharma by CRT Capital Mar 03 2015
Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
LIGAND PHARMACEUTICALS INC Financials Feb 28 2015
10-K for Ligand Pharmaceuticals, Inc. Feb 25 2015
LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2015
Glaxo Submits Another Revolade Application in the EU - Analyst Blog Feb 09 2015
Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape Feb 09 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 09 2015
Ligand meets 4Q profit forecasts Feb 09 2015
Ligand meets 4Q profit forecasts Feb 09 2015
Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
Q4 2014 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Feb 09 2015
Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog Feb 06 2015
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for... Feb 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK